Armata Pharmctcl Stock Price, News & Analysis

Armata Pharmaceuticals (NYSE American: ARMP) announced significant Q2 2025 developments, including a $15 million secured credit agreement with Innoviva and positive topline results from their Phase 1b/2a diSArm trial for AP-SA02, their lead S. aureus therapeutic candidate.

The company reported Q2 2025 financial results with grant revenue of $2.2 million, R&D expenses of $6.4 million, and cash position of $4.3 million. Additionally, Armata received $4.65 million in non-dilutive funding from the U.S. Department of Defense.

The diSArm trial met all primary endpoints, demonstrating improved clinical outcomes compared to standard antibiotic therapy with no treatment-related serious adverse events. Armata plans to initiate a Phase 3 pivotal trial in 2026 following an FDA end-of-Phase 2 meeting later this year.

Armata Pharmaceuticals (NYSE: ARMP) announced positive topline results from its Phase 1b/2a diSArm trial evaluating AP-SA02, an intravenous bacteriophage therapeutic for treating Staphylococcus aureus bacteremia. The study met all primary endpoints, with AP-SA02 showing significantly improved clinical outcomes compared to best available antibiotic therapy (BAT). Key findings include: - 88% responder rate in AP-SA02 treated subjects vs 58% for placebo at Test of Cure day 12 - 100% clinical response in AP-SA02 group vs 75% in placebo group at end of study - Effective against both MRSA and MSSA infections - No serious treatment-related adverse events observed - Successful manufacturing capacity of over 10,000 full treatment courses annually The trial represents a breakthrough in phage therapy for systemic infections, demonstrating both safety and efficacy in a randomized controlled setting.

Armata Pharmaceuticals (NYSE: ARMP) reported its Q1 2025 financial results and corporate updates. The company anticipates topline results from its Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia in H1 2025. Key financial highlights include: revenue of $0.5 million (down from $1.0M in Q1 2024), net loss of $6.5 million ($0.18 per share), and cash position of $11.7 million. The company secured additional funding through a $4.65 million non-dilutive DoD award and a $10 million secured credit agreement with Innoviva. R&D expenses decreased to $5.4 million from $8.0 million year-over-year, while G&A expenses remained relatively stable at $3.3 million.

Armata Pharmaceuticals (NYSE: ARMP) has received an additional $4.65 million in non-dilutive funding from the Department of Defense, bringing the total award to $26.2 million. The funding supports the development of AP-SA02, a phage-based treatment for complicated Staphylococcus aureus bacteremia (SAB). The Phase 1b/2a diSArm trial, which completed enrollment of 50 subjects in November 2024, evaluated AP-SA02 as an adjunct to best available antibiotic therapy. The study successfully achieved dose escalation to 5e10 PFU every six hours without significant adverse events. Notably, approximately half of the treated group showed evidence of phage persistence in blood, suggesting successful targeting of SAB reservoirs. Topline data is expected in Q2 2025, which will inform the optimal dosing for future pivotal trials.

Armata Pharmaceuticals (NYSE: ARMP) reported Q4 and full-year 2024 results, highlighting significant clinical progress. The company announced positive topline results from its Phase 2 Tailwind study of inhaled AP-PA02 for treating Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis patients, showing statistically significant bacterial reduction.

Q4 2024 financial highlights include:

• Grant revenue of $1.2M (vs $1.5M in Q4 2023)
• R&D expenses of $8.5M (vs $7.9M in Q4 2023)
• Net income of $2.6M or $0.07 per basic share
• Cash position of $14.8M as of December 31, 2024

The company secured a $10M secured credit agreement with Innoviva Strategic Opportunities in March 2025. Armata also completed enrollment in its Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia, with topline results expected in H1 2025.

Armata Pharmaceuticals (NYSE American: ARMP) has secured a $10 million credit agreement with Innoviva Strategic Opportunities , its largest shareholder. The loan facility comes with a 14.0% annual interest rate and matures on March 12, 2026.

The proceeds will support the development of Armata's lead therapeutic phage candidates: AP-PA02 targeting Pseudomonas aeruginosa infections and AP-SA02 for Staphylococcus aureus infections. The funding will specifically enable the company to complete its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia and prepare for an end-of-Phase 2 FDA meeting.

Additionally, Armata amended three existing credit agreements with Innoviva, extending their maturity dates to March 12, 2026. The company continues to seek additional funding sources, including non-dilutive options, to support late-stage clinical trials.

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics, has announced that CEO Dr. Deborah Birx will present at the 7th Annual Bacteriophage Therapy Summit in Boston, MA. The presentation is scheduled for Thursday, March 13, 2025, at 9:00am ET.

The company focuses on developing high-purity pathogen-specific bacteriophage therapeutics to address antibiotic-resistant and difficult-to-treat bacterial infections.

Armata Pharmaceuticals (NYSE: ARMP) announced positive topline results from its Phase 2 Tailwind trial of AP-PA02, an inhaled multi-phage therapeutic for treating chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients.

The trial demonstrated statistically significant reduction of P. aeruginosa in lung sputum, with effects persisting two weeks after treatment completion. A post-hoc analysis showed significant bacterial reduction at day 17 (P=0.05) and day 24 (P=0.015) compared to placebo. Approximately one-third of subjects treated with phage monotherapy showed at least a 2-log CFU reduction.

The treatment was well-tolerated with mostly mild adverse events, though one possibly related serious adverse event requiring hospitalization was reported. The study suggests AP-PA02 alone could be as effective as combination therapy with antibiotics.

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant bacterial infections, announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting in Boston, MA. The presentation is scheduled for 1:15pm ET on November 19th, 2024.